| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -105,872 | -5,626 |
| Proceeds from the sale of ordinary shares | 20 | 20 |
| Proceeds from option exercises | 278 | - |
| Repurchase of shares to satisfy tax withholding | 2,055 | 1,377 |
| Net cash used in financing activities | -1,757 | -1,357 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 136,976 | 244,130 |
| Cash and cash equivalents at beginning of period | 38,633 | - |
| Cash and cash equivalents at end of period | 175,609 | - |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)